Are the GH treatment doses in use within secretion rates of healthy children?

Lundberg E1, Andersson B1, Kriström B1, Rosberg S2 and Albertsson Wikland K2
Inst of Clinical Sciences, Pediatrics1, Umeå University, Umeå, ·Dep of Physiology/Endocrin, Inst of Neuroscience/physiology,The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden

P1-631 ESPE Paris 2016

Aim to calculate the bioavailable immunoreactive rhGH after sc injection in relation to injected GH-dose and compare the result to GH-secretory rate calculated in healthy children; to investigate factors that influenced bioavailability (BA).

Background GH-secretion in children with normal growth rates can be used to optimize rhGH-treatment doses. For healthy children endogenous GH-secretion ranges within 0.1-11 U/24h in pre/early puberty and within 4-40 U/24h in mid-puberty

Result

BA is presented as median and coefficient of variation, CV, and is expressed as % of the injected dose.
No dose dependency was found for GH33 vs GH67, p=0.21, Fig1A
A positive concentration dependency of GH 4 vs 16IU/ml, p=0.035. Fig1B

Fig1A Clinical-setting
BA 71%(43)  Fig 1B Experimental-setting
BA 84%(35)

BA for GH33 71%(34), range 10-176, for GH67 75(31), range 16-143

In total, 22% of the variation in BA could be explained by the variables BMI SDS, GH peak width and the GH-level at baseline, interpreted as proxy variables for the depth of the injection.

Material GH-curves from the children who were yearly followed up to 8 years after GH dose 33 (GH33) or 67 (GH67) µg/kg/d, given as a sc injection at 90° angle in the thigh, using a 12mm needle.
For this analysis of BA, only the GH-curves without sign of endogenous secretion and coming back to their pre-injection GH level were used.
Experimental-setting 59 GH-curves from 15 children, diagnose MPHD; GH33, concentration 4 or 16IU/ml, given by a nurse at 09:00; blood samples were drawn every 30 min until 6h and thereafter every 2h until 24h after the injection.
Clinical-setting 154 GH-curves from 117 children, diagnose IGHD/ISS; GH33 or GH67, injected by the patient/parents at 18:00; blood samples were drawn every 2h until 16h after the injection.

Methods The cumulative amount of GH in the serum was calculated with the formula:
AUC0 ∞ = 0.066(Vp) x 0.046(Vs) x kg = uptake (mU converted to Unit) which was compared with the injected dose (U)=100% which gives the BA in %.

Conclusion

• The uptake of injected GH was around 70% without dose dependency, 33 - 67 µg/kg.
• A great intra- and inter-individual variation, influenced by the injection-depth.
• Bioavailable GH from GH33 and GH67 µg/kg/d corresponds to the lower range of GH secretion rates in healthy children.
Bioavailability = 70% of injected GH estimated from Clinical-setting vs GH-secretion rate (U/24h) estimated from healthy children

Exogenous dosing consequences:
GH33 in prepub 25kg child gives 825µg=2.5U/24h (70%=1.75U/24h, lower red arrow)
GH67 in pub 50kg child gives 3350µg=10U/24h (70%=7U/24h, upper red arrow)
Factor 3 used to convert µ to U.

Disclosure: EL, BA, SR, KAW has nothing to declare;
BK has received consultant honoraria from Pfizer.